-
Merz heads to Gulf as Germany looks to diversify trade ties
-
Selection process for future Olympic hosts set for reform
-
Serbian minister on trial over Trump-linked hotel plan
-
UK PM says Mandelson 'lied', regrets appointing him US envoy
-
Cochran-Siegle tops first Olympic downhill training
-
Gaza health officials say strikes kill 21 after Israel says shots wounded officer
-
Injured Vonn's Olympic bid is 'inspirational', ski stars say
-
Albania arrests 20 for toxic waste trafficking
-
US-Africa trade deal renewal only 'temporary breather'
-
Mir sets pace on Sepang day two, Yamaha absent
-
Xi, Putin hail 'stabilising' China-Russia alliance
-
GSK boosted by specialty drugs, end to Zantac fallout
-
UK's ex-prince leaves Windsor home amid Epstein storm: reports
-
Sky is the limit for Ireland fly-half Prendergast, says captain Doris
-
Stocks fluctuate after Wall St AI-fuelled sell-off
-
Feyi-Waboso reminds England great Robinson of himself
-
Starmer faces MPs as pressure grows over Mandelson scandal
-
HRW urges pushback against 'aggressive superpowers'
-
Russia demands Ukraine give in as UAE talks open
-
Gaza civil defence says 17 killed in strikes after Israel says shots wounded officer
-
France's Kante joins Fenerbahce after Erdogan 'support'
-
CK Hutchison launches arbitration over Panama Canal port ruling
-
Stocks mostly rise as traders ignore AI-fuelled sell-off on Wall St
-
Acclaimed Iraqi film explores Saddam Hussein's absurd birthday rituals
-
On rare earth supply, Trump for once seeks allies
-
Ukrainian chasing sumo greatness after meteoric rise
-
Draper to make long-awaited return in Davis Cup qualifier
-
Can Ilia Malinin fulfil his promise at the Winter Olympics?
-
CK Hutchison begins arbitration against Panama over annulled canal contract
-
UNESCO recognition inspires hope in Afghan artist's city
-
Ukraine, Russia, US negotiators gather in Abu Dhabi for war talks
-
WTO must 'reform or die': talks facilitator
-
Doctors hope UK archive can solve under-50s bowel cancer mystery
-
Stocks swing following latest AI-fuelled sell-off on Wall St
-
Demanding Dupont set to fire France in Ireland opener
-
Britain's ex-prince Andrew leaves Windsor home: BBC
-
Coach plots first South Africa World Cup win after Test triumph
-
Spin-heavy Pakistan hit form, but India boycott risks early T20 exit
-
Japan eyes Premier League parity by aligning calendar with Europe
-
Whack-a-mole: US academic fights to purge his AI deepfakes
-
Love in a time of war for journalist and activist in new documentary
-
'Unprecedented mass killing': NGOs battle to quantify Iran crackdown scale
-
Seahawks kid Cooper Kupp seeks new Super Bowl memories
-
Thousands of Venezuelans march to demand Maduro's release
-
AI, manipulated images falsely link some US politicians with Epstein
-
Move on, says Trump as Epstein files trigger probe into British politician
-
Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant
-
CHAR Technologies Licenses High-Temperature Pyrolysis Technology to GazoTech SAS for Entry Into European Markets
-
Arteta backs Arsenal to build on 'magical' place in League Cup final
-
Evil Empire to underdogs: Patriots eye 7th Super Bowl
US finds monkeypox vaccine highly effective in early data
The monkeypox vaccine is highly effective, protecting people as early as two weeks after the first dose, the US Centers for Disease Control and Prevention said Wednesday.
A preliminary analysis posted by the agency found that between July 31 and September 3, unvaccinated people had 14 times the risk of acquiring monkeypox disease compared to people who were vaccinated, 14 days or more after their first shot.
The results were based on confirmed infections from 32 jurisdictions across the country. The US has seen more than 25,000 cases in the current outbreak, which began in May this year and has primarily affected men who have sex with men.
"These new data provide us with a level of cautious optimism that the vaccine is working as intended," CDC director Rochelle Walensky told reporters during a briefing.
"Even in light of these promising data, we strongly recommend people receive two doses of Jynneos vaccine spaced out 28 days apart to ensure durable, lasting immune protection against monkeypox," she added.
Despite being approved, there is not yet a confirmed efficacy estimate for the Jynneos vaccine against monkeypox, because prior studies had only looked at animals and measured human immune response data.
More than 66,000 cases of monkeypox have been detected globally, but new infections have been falling since August.
The US has administered more than 680,000 doses of the Jynneos vaccine, focusing its efforts on gay and bisexual men, as well as transgender and gender diverse people.
White House monkeypox response deputy coordinator Demetre Daskalakis said the rollout strategy was moving into a new phase in which the vaccine would be offered to people with no prior exposure, rather than after a known exposure.
"This new strategy means that more people who might be at present or future risk for monkeypox now qualify for the vaccine," he said.
In order to reduce stigma, new guidance would allow health providers to administer the vaccine in less visible areas, including the shoulder or upper back, instead of the forearm, he added.
C.Kovalenko--BTB